If most of your revenue comes from one treatment line, you do not have a marketing problem, you have a concentration problem, and the fix is not a longer service menu. It is one deliberate second pillar, chosen by patient overlap rather than margin, launched to your existing patient list before you spend a dollar on paid campaigns.
This shows up most often in practices that are genuinely busy. The injectable calendar is full, the toxin patients rebook on schedule, the reviews are strong. Every one of those strengths is resting on a single point of exposure.
"How much of my revenue actually comes from one treatment?" The 10 minute check
Before any strategy conversation, pull three numbers for each treatment line. Last twelve months, no estimates, straight from your practice management system.
- Share of revenue. What percentage of collected revenue came from each line.
- Share of first consults. Of patients who came in for the first time, what did they book.
- Share of repeat visits. Of all return visits, which line brought them back.
Then read the gaps, because the gaps are the diagnosis.
- Revenue high, first consults low. You are harvesting an existing patient base, not acquiring. Growth is capped at the size of your current list.
- First consults high, repeat visits low. You are buying patients who do not come back. Every month starts at zero.
- One line above roughly half in all three columns. That is single-pillar dependence. Your practice's financial health now tracks one category's pricing, one device cycle and one manufacturer's product roadmap.
Most owners know their total revenue and their busiest treatment. The three-column version is a different conversation, and it takes about ten minutes to produce.
Why being known for one thing stops protecting you the day the clinic down the road buys the same device
Concentration feels like positioning. You are the injector in your market. You are the practice people drive past two other clinics to reach. That reputation is real, and it is worth protecting.
But reputation built on a treatment rather than a practice has a specific failure mode. The moment a competitor buys the same device or stocks the same product, the thing you are known for becomes something two of you offer. Patients cannot assess injection technique from a website. What they can assess is price. So the negotiation moves to the one variable they understand, and you are defending margin on the line that carries most of your revenue.
Practices with a genuine second pillar negotiate differently. The patient who comes for one treatment and stays for a second is not comparing single prices, they are in a relationship with a practice. That is a pricing position, not just a revenue position.
Why a single injectable line is a fragile base
Treatment categories do not move in one direction together. A category can soften while individual practices and products inside it keep growing, because demand concentrates with whoever has built it. At practice level that is the whole argument: in a soft category, the practice with two pillars and an owned patient list keeps filling the calendar while the single-pillar practice down the road discounts.
The product landscape moves underneath you as well. When a longer-duration product arrives in a category you depend on, that is excellent for the patient and it is also fewer visits per patient per year for you. A revenue-per-patient change like that is absorbed easily by a practice with a second pillar. A single-pillar practice absorbs it with no cushion.
Choose the second pillar by patient overlap, not margin
The common mistake is picking pillar two from a margin table. Headline margin is the least useful input you have, because a high-margin service your patients do not want is a staffing cost with a website page.
Ask a better question: what are your current patients already asking about, or already buying somewhere else?
That information is sitting in your practice right now. Your front desk hears it weekly. Your injectors hear it mid-appointment. Your consult notes contain it. Pull it deliberately:
- Ask every injector to log, for two weeks, every treatment a patient asked about that you do not currently offer or do not actively promote.
- Review consult notes for declined or deferred recommendations.
- Ask your top 50 patients directly. One question, by email: what are you currently going elsewhere for.
Then filter the candidates on three things, in this order.
- Patient overlap. Does your existing base want it. This is the only one you cannot buy your way out of.
- Visit frequency. How often does a patient return. A treatment with a monthly or quarterly cycle builds a far more predictable calendar than one with a six to twelve month cycle, even at a lower price point. Predictability of return is worth more than a strong one-time ticket.
- Clinical and brand fit. Can you deliver it at the standard your reputation is built on. If not, it is not a pillar, it is a liability.
Margin matters, but it is a fourth filter, not a first.
Launch it to your own patients before you spend on ads
Most second pillars fail at launch, not at selection, and they fail because the practice went straight to paid campaigns. You are then paying to acquire cold patients for an offer you have never tested, with no proof, no before and after library and no internal confidence at the front desk.
Sequence it properly.
Weeks one to four, your own list. Email your existing patients with a clear explanation of what the treatment is, who it is for and why you added it. Run patient reactivation SMS to the segment most likely to want it, which your concentration check has already identified. Your owned list is the cheapest, warmest demand you will ever have access to, and it compounds. These patients already trust your hands.
Weeks four to eight, build the proof. Document results from those first cases. Before and after sliders, short video of the practitioner explaining the protocol, education-first content that answers the questions patients actually asked you. Give the treatment a real consult path on your site, not a line on a menu.
Week eight onward, add paid and AI search visibility. Now you have conversion data, proof assets and a team that can speak confidently about the treatment. Meta, Google and TikTok campaigns have something to point at. Your practice can start showing up in the answers patients get when they research the treatment, which is increasingly where consideration begins.
What to stop offering
Adding a pillar without removing anything is how booking pages become unreadable and staff hours disappear.
Go back to your three-column analysis and find the long tail: lines carrying a small share of revenue, few first consults and almost no repeat visits. Those services consume training, room time, inventory, booking page real estate and front desk explanation, and they return very little. They also blur what you are known for, which is the exact thing you are trying to protect.
Retire them cleanly. Stop promoting them first, remove them from the booking flow, honour existing packages, and redirect those patients to the line that serves them better. Patients rarely object. They mostly notice that booking got easier.
The practice-level version of this
Two pillars is not a bigger menu. It is a second patient journey with its own demand engine, its own proof and its own content, built from patients you already have.
That is the work we do with premium practices every day: the concentration check, the pillar selection, the list-first launch and the campaigns and AI search visibility that follow once the offer converts. If you want a read on where your revenue is actually concentrated and what your second pillar should be, book a free 15 minute discovery call and we will walk through your numbers with you.
Frequently asked questions
How do I diversify revenue without diluting what we are known for?
Add one pillar, not a menu. Dilution happens when a practice adds five services with no demand engine behind any of them. A single second pillar, chosen because your existing patients already want it, and given its own consult path, proof assets and content, reinforces your reputation rather than scattering it.
Should I choose the second treatment with the highest margin?
No. Filter on patient overlap first, visit frequency second, clinical and brand fit third, and margin fourth. A high-margin service your patients do not want is a staffing cost with a website page, while a treatment with a monthly or quarterly return cycle builds far more calendar predictability than a high-ticket one they book once a year.
How long before a second pillar actually produces revenue?
Plan on a staged launch. Weeks one to four go to your existing patient list via email and reactivation SMS. Weeks four to eight build proof from those first cases, before and afters, video and education content. From week eight you add paid campaigns and AI search visibility once the offer has conversion data behind it.
Is the injectable market actually declining?
The wider category is growing. Medical aesthetics has eclipsed $17 billion and is growing by more than $1 billion per year. But individual lines move independently. Some manufacturers have reported declines in their injectable lines in the same period that others gained filler share in a category they described as soft. Demand concentrates with whoever has built it.
What should I remove when I add a new treatment line?
The long tail your own numbers expose: lines with a small share of revenue, few first consults and almost no repeat visits. Stop promoting them, remove them from the booking flow, honour existing packages and redirect those patients. It frees the staff hours and booking page clarity your second pillar needs.
